1. Perception of risk: The state of COX-2 selective inhibitors

   • Lee S. Simon
   • Vibeke Strand

   Invited Commentary Pages: 163 - 166

2. Web alert

   News Pages: 167 - 168

3. Treatment of reactive arthritis with azithromycin

   • Christopher T. Ritchlin

   Clinical Trials Report Pages: 171 - 171

4. Doxycycline in undifferentiated spondyloarthropathy

   • Christopher T. Ritchlin

   Clinical Trials Report Pages: 171 - 172

5. Primate spondyloarthropathy

   • Bruce M. Rothschild

   OriginalPaper Pages: 173 - 181

6. Novel therapies for ankylosing spondylitis

   • Walter P. Maksymowych

   OriginalPaper Pages: 182 - 187

7. Gut inflammation in the spondyloarthropathies

   • Herman Mielants
   • Filip De Keyser
   • Filip Van den Bosch

   OriginalPaper Pages: 188 - 194

8. Outcome measures in psoriatic arthritis

   • Arthur Kavanaugh
   • Sarah Cassell

   OriginalPaper Pages: 195 - 200

9. Recent advances in reactive arthritis

   • Ines Colmegna
   • Luis R. Espinoza

   OriginalPaper Pages: 201 - 207

10. What do epidemiologic studies tell us about hyperuricemia and cardiovascular disease and death?

    • Christopher W. Wu
    • Robert Terkeltaub

    Clinical Trials Report Pages: 211 - 212

11. Calcium-containing crystals and osteoarthritis: Implications for the clinician

    • Christopher W. Wu
    • Robert Terkeltaub
    • Kenneth C. Kalunian

    OriginalPaper Pages: 213 - 219

12. Diet, alcohol, and gout: How do we advise patients given recent developments?

    • Hyon K. Choi

    OriginalPaper Pages: 220 - 226

13. Renal urate handling: Clinical relevance of recent advances

    • Naohiko Anzai
    • Atsushi Enomoto
    • Hitoshi Endou

    OriginalPaper Pages: 227 - 234

14. Recent advances in the epidemiology of gout

    • Kenneth G. Saag
    • Ted R. Mikuls

    OriginalPaper Pages: 235 - 241

15. Gout treatment: What is evidence-based and how do we determine and promote optimized clinical care?

    • Ted R. Mikuls
    • Kenneth G. Saag

    OriginalPaper Pages: 242 - 249